Lundholm et al. found that NKG2D ligand-expressing prostate tumour-derived EVs selectively induced the downregulation of NKG2D on natural killer (NK) and CD8+ T cells, leading to damaged cytotoxic T cell function in vitro. The gene discussed is KLRK1; the disease is prostate neoplasm.